IMFORTE . Desde JazzPharma Siguen Anclados en los Resultados del Corte Intermedio Realizado Por ROCHE en 2024 Cuyos Datos Fueron Presentados en ASCO25 , Revista Especializada Y en la US-FDA ... Repetidos Ya Miles de Veces Sin Variar Ni una Sola Coma ... Queda Claro Qué Nada Nuevo Tienen ... Y Eso a Fecha de Hoy Da Qué Pensar ...
22 noviembre 2012
Yondelis , Cientificos Italianos dan a Conocer , en la Prestigisa revista Oncologica EJC del Mes de Noviembre , Resultados que podrían tener " Importantes Implicaciones Clinicas " en Pacientes ( Tiroides /// Colón ) con un Nivel Alto de HMGA .
The Impairment of the High Mobility Group A (HMGA) Protein Function Contributes to the Anticancer Activity of Trabectedin .
EJC . Published Online , 13 November 2012.
... We first report that trabectedin has a higher cytotoxic effect on thyroid and colon carcinoma cells expressing abundant levels of HMGAs in comparison with cells not expressing them. Then, we have shown that trabectedin treatment displaces HMGA proteins from the HMGA-responsive promoters, including ATM promoter, impairing their transcriptional activity. Finally, we report a synergism between Ionising Radiations and trabectedin treatment restricted to the HMGA-overexpressing cancer cells. This result might have important clinical implications since it would suggest the use of trabectedin for the treatment of neoplasias expressing abundant HMGA levels that are frequently associated to chemoresistance and poor prognosis.
...